Literature DB >> 21663454

Characterization of the human artemis promoter by heterologous gene expression in vitro and in vivo.

Megan M Multhaup1, Sweta Gurram, Kelly M Podetz-Pedersen, Andrea D Karlen, Debra L Swanson, Nikunj V Somia, Perry B Hackett, Morton J Cowan, R Scott McIvor.   

Abstract

Artemis is an endonucleolytic enzyme involved in nonhomologous double-strand break repair and V(D)J recombination. Deficiency of Artemis results in a B- T- radiosensitive severe combined immunodeficiency, which may potentially be treatable by Artemis gene transfer into hematopoietic stem cells. However, we recently found that overexpression of Artemis after lentiviral transduction resulted in global DNA damage and increased apoptosis. These results imply the necessity of effecting natural levels of Artemis expression, so we isolated a 1 kilobase DNA sequence upstream of the human Artemis gene to recover and characterize the Artemis promoter (APro). The sequence includes numerous potential transcription factor-binding sites, and several transcriptional start sites were mapped by 5' rapid amplification of cDNA ends. APro and deletion constructs conferred significant reporter gene expression in vitro that was markedly reduced in comparison to expression regulated by the human elongation factor 1-α promoter. Ex vivo lentiviral transduction of an APro-regulated green fluorescent protein (GFP) construct in mouse marrow supported GFP expression throughout hematopoeitic lineages in primary transplant recipients and was sustained in secondary recipients. The human Artemis promoter thus provides sustained and moderate levels of gene expression that will be of significant utility for therapeutic gene transfer into hematopoeitic stem cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663454      PMCID: PMC3183654          DOI: 10.1089/dna.2011.1244

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  29 in total

1.  Requirement for an interaction of XRCC4 with DNA ligase IV for wild-type V(D)J recombination and DNA double-strand break repair in vivo.

Authors:  U Grawunder; D Zimmer; P Kulesza; M R Lieber
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

Review 2.  Initiation of V(D)J recombinations in a cell-free system by RAG1 and RAG2 proteins.

Authors:  D C van Gent; J F McBlane; D A Ramsden; M J Sadofsky; J E Hesse; M Gellert
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle.

Authors:  S E Lee; R A Mitchell; A Cheng; E A Hendrickson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination.

Authors:  M A Oettinger; D G Schatz; C Gorka; D Baltimore
Journal:  Science       Date:  1990-06-22       Impact factor: 47.728

5.  Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps.

Authors:  J F McBlane; D C van Gent; D A Ramsden; C Romeo; C A Cuomo; M Gellert; M A Oettinger
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

6.  Two promoters of different strengths control the transcription of the mouse alpha-amylase gene Amy-1a in the parotid gland and the liver.

Authors:  U Schibler; O Hagenbüchle; P K Wellauer; A C Pittet
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

7.  Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates.

Authors:  C Zhu; M A Bogue; D S Lim; P Hasty; D B Roth
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

8.  Genomic structure and chromosomal assignment of the mouse Ku70 gene.

Authors:  Y Takiguchi; A Kurimasa; F Chen; P E Pardington; T Kuriyama; R T Okinaka; R Moyzis; D J Chen
Journal:  Genomics       Date:  1996-07-01       Impact factor: 5.736

9.  Efficacy of gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Julia Hauer; Annick Lim; Capucine Picard; Gary P Wang; Charles C Berry; Chantal Martinache; Frédéric Rieux-Laucat; Sylvain Latour; Bernd H Belohradsky; Lily Leiva; Ricardo Sorensen; Marianne Debré; Jean Laurent Casanova; Stephane Blanche; Anne Durandy; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2010-07-22       Impact factor: 91.245

10.  V(D)J recombination: broken DNA molecules with covalently sealed (hairpin) coding ends in scid mouse thymocytes.

Authors:  D B Roth; J P Menetski; P B Nakajima; M J Bosma; M Gellert
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

View more
  3 in total

1.  Role of transgene regulation in ex vivo lentiviral correction of artemis deficiency.

Authors:  Megan M Multhaup; Kelly M Podetz-Pedersen; Andrea D Karlen; Erik R Olson; Roland Gunther; Nikunj V Somia; Bruce R Blazar; Morton J Cowan; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2015-04-13       Impact factor: 5.695

2.  Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.

Authors:  Divya Punwani; Misako Kawahara; Jason Yu; Ukina Sanford; Sushmita Roy; Kiran Patel; Denise A Carbonaro; Andrea D Karlen; Sara Khan; Kenneth Cornetta; Michael Rothe; Axel Schambach; Donald B Kohn; Harry L Malech; R Scott McIvor; Jennifer M Puck; Morton J Cowan
Journal:  Hum Gene Ther       Date:  2016-09-07       Impact factor: 5.695

3.  Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID.

Authors:  Sabine Charrier; Chantal Lagresle-Peyrou; Valentina Poletti; Michael Rothe; Grégory Cédrone; Bernard Gjata; Fulvio Mavilio; Alain Fischer; Axel Schambach; Jean-Pierre de Villartay; Marina Cavazzana; Salima Hacein-Bey-Abina; Anne Galy
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-13       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.